Tumor-suppressive Effects of Psoriasin (S100A7) Are Mediated through the β-Catenin/T Cell Factor 4 Protein Pathway in Estrogen Receptor-positive Breast Cancer Cells*
Open Access
- 30 December 2011
- journal article
- Published by Elsevier BV
- Vol. 286 (52), 44845-44854
- https://doi.org/10.1074/jbc.m111.225466
Abstract
No abstract availableThis publication has 44 references indexed in Scilit:
- The Role of LEF/TCF Factors in Neoplastic TransformationCurrent Molecular Medicine, 2008
- The S100A7-c-Jun Activation Domain Binding Protein 1 Pathway Enhances Prosurvival Pathways in Breast CancerCancer Research, 2005
- WNT and β-catenin signalling: diseases and therapiesNature Reviews Genetics, 2004
- Axin-mediated CKI phosphorylation of β-catenin at Ser 45: a molecular switch for the Wnt pathwayGenes & Development, 2002
- Molecular architecture of adherens junctionsCurrent Opinion in Cell Biology, 2001
- Control of β‐Catenin Signaling in Tumor DevelopmentAnnals of the New York Academy of Sciences, 2000
- Psoriasin (S100A7) Expression and Invasive Breast CancerThe American Journal of Pathology, 1999
- Human Epidermal Differentiation Complex in a Single 2.5 Mbp Long Continuum of Overlapping DNA Cloned in Bacteria Integrating Physical and Transcript MapsJournal of Investigative Dermatology, 1999
- The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumorsOncogene, 1999
- Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.1994